---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216758"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2026-05-11T20:08:24+00:00"
generated_at: "2026-05-11T22:31:49.381959+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sana Q1 net loss $47.2M, cash $101.1M; Mayo $25M equity; SC451/SG293 trials on track for 2026

## Summary
- Net loss of $47.2M ($0.17/sh); R&D expenses $28.7M (down from $37.2M YoY).
- Cash & securities $101.1M; pro forma $128.9M including Mayo $25M equity and ATM activity.
- Mayo collaboration to accelerate SC451; Mayo made $25M equity investment with option for another $25M.
- SC451 Phase 1 IND filing expected later this year; SG293 clinical data presented May 12 at ASGCT.
- SG227 (BCMA CAR) expected to begin clinical testing as early as mid-2027, contingent on SG293 data.

## SEC filing metadata
- accession: 0001193125-26-216758
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2026-05-11T20:08:24+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/0001193125-26-216758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/sana-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216758
- JSON: https://secwatch.observer/filing/0001193125-26-216758.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216758.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for first quarter 2026.
  - Period: first quarter 2026
  - Result: reported results
  source text: On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/0001193125-26-216758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.